GENETHERA INC

2022 Q4 Form 10-Q Financial Statement

#000157587222001091 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00
YoY Change
Cash & Equivalents $0.00 $0.00
Short-Term Investments
Other Short-Term Assets $0.00 $1.020K
YoY Change -100.0% -91.72%
Inventory
Prepaid Expenses $0.00 $1.022K
Receivables
Other Receivables
Total Short-Term Assets $0.00 $1.022K
YoY Change -100.0% -91.7%
LONG-TERM ASSETS
Property, Plant & Equipment $1.320K $6.600K
YoY Change -80.0% -44.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $1.320K $6.600K
YoY Change -80.0% -44.44%
TOTAL ASSETS
Total Short-Term Assets $0.00 $1.022K
Total Long-Term Assets $1.320K $6.600K
Total Assets $1.320K $7.622K
YoY Change -82.68% -68.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $91.07K $81.07K
YoY Change 12.34% 0.0%
Accrued Expenses $7.638M $7.173M
YoY Change 6.48% 7.51%
Deferred Revenue
YoY Change
Short-Term Debt $97.80K $83.80K
YoY Change 16.71% 4.36%
Long-Term Debt Due $716.0K $721.0K
YoY Change -0.68% 1.51%
Total Short-Term Liabilities $8.543M $8.059M
YoY Change 6.01% 6.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.543M $8.059M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $8.543M $8.065M
YoY Change 5.93% 6.91%
SHAREHOLDERS EQUITY
Retained Earnings -$32.68M -$32.00M
YoY Change 2.13%
Common Stock $35.33K $30.97K
YoY Change 14.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$8.541M -$8.051M
YoY Change
Total Liabilities & Shareholders Equity $1.320K $7.622K
YoY Change -82.68% -68.5%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
25800
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
25800
CY2022Q3 gthr Convertible Notes Payable Current Net Of Discount
ConvertibleNotesPayableCurrentNetOfDiscount
72000
us-gaap Profit Loss
ProfitLoss
-406256
CY2021Q4 gthr Convertible Notes Payable Current Net Of Discount
ConvertibleNotesPayableCurrentNetOfDiscount
64500
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
716035
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
720969
CY2022Q3 us-gaap Liabilities
Liabilities
8542764
CY2021Q4 us-gaap Liabilities
Liabilities
8178990
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
dei Entity File Number
EntityFileNumber
000-27237
dei Entity Registrant Name
EntityRegistrantName
GeneThera, Inc.
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35333319
CY2022Q3 us-gaap Cash
Cash
0
dei Entity Central Index Key
EntityCentralIndexKey
0001017110
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0622463
dei Entity Address Address Line1
EntityAddressAddressLine1
3051 W. 105th Ave.
dei Entity Address Address Line2
EntityAddressAddressLine2
350251
dei Entity Address City Or Town
EntityAddressCityOrTown
Westminster
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80035
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
587-5100
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Cash
Cash
0
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1022
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35333319
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35333319
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34083319
CY2022Q3 us-gaap Assets
Assets
1320
CY2021Q4 us-gaap Assets
Assets
6302
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
91070
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
81070
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7637859
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7286651
CY2022Q3 us-gaap Assets Current
AssetsCurrent
0
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1022
CY2022Q3 gthr Property And Equipment Automobile Trucks
PropertyAndEquipmentAutomobileTrucks
26400
CY2021Q4 gthr Property And Equipment Automobile Trucks
PropertyAndEquipmentAutomobileTrucks
26400
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25080
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21120
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1320
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5280
CY2022Q3 us-gaap Other Assets
OtherAssets
0
CY2021Q4 us-gaap Other Assets
OtherAssets
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34083319
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
35333
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
34083
CY2022Q3 gthr Common Stock To Be Issued
CommonStockToBeIssued
53572
CY2021Q4 gthr Common Stock To Be Issued
CommonStockToBeIssued
53572
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24021314
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23985064
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32677702
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32271446
CY2022Q3 gthr Stockholders Equity1
StockholdersEquity1
-8541444
CY2021Q4 gthr Stockholders Equity1
StockholdersEquity1
-8172688
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1320
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6302
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-125573
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-243866
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7197
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
124400
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
51128
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
378081
CY2022Q3 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
116500
CY2021Q3 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
116500
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
349500
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
349500
CY2022Q3 us-gaap Depreciation
Depreciation
1320
CY2021Q3 us-gaap Depreciation
Depreciation
1320
us-gaap Depreciation
Depreciation
3960
us-gaap Depreciation
Depreciation
3960
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
125017
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
242220
us-gaap Operating Expenses
OperatingExpenses
404588
us-gaap Operating Expenses
OperatingExpenses
731541
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-125017
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-242220
us-gaap Operating Income Loss
OperatingIncomeLoss
-404588
us-gaap Operating Income Loss
OperatingIncomeLoss
-731541
CY2022Q3 us-gaap Other Expenses
OtherExpenses
0
CY2021Q3 us-gaap Other Expenses
OtherExpenses
0
us-gaap Other Expenses
OtherExpenses
0
us-gaap Other Expenses
OtherExpenses
0
CY2022Q3 us-gaap Interest Expense
InterestExpense
556
CY2021Q3 us-gaap Interest Expense
InterestExpense
1646
us-gaap Interest Expense
InterestExpense
1668
us-gaap Interest Expense
InterestExpense
4938
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-556
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1646
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1668
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4938
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-125573
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-243866
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-406256
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-736479
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Profit Loss
ProfitLoss
-736479
CY2022Q3 gthr Loss Per Common Share Basic And Diluted
LossPerCommonShareBasicAndDiluted
0
CY2021Q3 gthr Loss Per Common Share Basic And Diluted
LossPerCommonShareBasicAndDiluted
-0.01
gthr Loss Per Common Share Basic And Diluted
LossPerCommonShareBasicAndDiluted
-0.01
gthr Loss Per Common Share Basic And Diluted
LossPerCommonShareBasicAndDiluted
-0.03
gthr Weighted Average Common Shares Outstanding Basic And Diluted
WeightedAverageCommonSharesOutstandingBasicAndDiluted
25352148
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-8012017
CY2022Q3 gthr Weighted Average Common Shares Outstanding Basic And Diluted
WeightedAverageCommonSharesOutstandingBasicAndDiluted
34203481
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
361208
CY2021Q3 gthr Weighted Average Common Shares Outstanding Basic And Diluted
WeightedAverageCommonSharesOutstandingBasicAndDiluted
27756635
gthr Weighted Average Common Shares Outstanding Basic And Diluted
WeightedAverageCommonSharesOutstandingBasicAndDiluted
34113858
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
373946
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2566
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1327
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
0
us-gaap Interest Paid Net
InterestPaidNet
0
CY2021Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6000
CY2021Q3 gthr Shares Issued For Advisory Amount
SharesIssuedForAdvisoryAmount
198800
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-243866
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-8051082
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-8415871
CY2022Q3 gthr Shares Issued For Services Amount
SharesIssuedForServicesAmount
0
CY2022Q3 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-125573
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-8541444
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-7680504
gthr Shares Issued For Advisory Amount
SharesIssuedForAdvisoryAmount
365900
us-gaap Net Income Loss
NetIncomeLoss
-736479
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-8051082
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-8172688
gthr Shares Issued For Services Amount
SharesIssuedForServicesAmount
24500
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
13000
us-gaap Net Income Loss
NetIncomeLoss
-406256
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-8541444
us-gaap Profit Loss
ProfitLoss
-406256
us-gaap Profit Loss
ProfitLoss
-736479
us-gaap Share Based Compensation
ShareBasedCompensation
0
us-gaap Share Based Compensation
ShareBasedCompensation
0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3960
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3960
gthr Shares Issued For Services
SharesIssuedForServices
37500
gthr Shares Issued For Services
SharesIssuedForServices
359900
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1022
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0
us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
0
us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
0
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
0
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
0
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7500
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
9500
gthr Increase Decrease In Loans To Shareholders
IncreaseDecreaseInLoansToShareholders
-4934
gthr Increase Decrease In Loans To Shareholders
IncreaseDecreaseInLoansToShareholders
-10827
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2566
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1327
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Organization and nature of operations</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include GeneThera, Inc. and its wholly owned subsidiary GeneThera, Inc. (Colorado) (collectively, the “Company”). The Company had a long-standing research collaboration with GTI Research.</div></div> <div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is a biotechnology company that develops molecular assays and therapeutics for the detection and treatment for COVID-19 and other zoonotic diseases.</div></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation.</div></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-wrap; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain prior period amounts may have been reclassified to conform to current period presentation.</div></div>
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32677702
CY2022Q3 gthr Working Capital
WorkingCapital
-8542764
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1320
CY2022Q3 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
816667
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
24500
CY2022Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
433333
CY2022Q3 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
13000
CY2022Q3 gthr Common Stock Issued Per Share
CommonStockIssuedPerShare
0.03
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
180000
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
6308123
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5958623
CY2022Q3 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
96202
CY2021Q4 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
94534
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1233535
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1233494
CY2022Q3 gthr Accrued Liabilities Current1
AccruedLiabilitiesCurrent1
7637860
CY2021Q4 gthr Accrued Liabilities Current1
AccruedLiabilitiesCurrent1
7286651
CY2022Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.08
CY2022Q3 gthr Debt Instrument Interest Rate Percentage
DebtInstrumentInterestRatePercentage
0.08
CY2022Q3 gthr Outstanding Principal
OutstandingPrincipal
54500
CY2021Q4 gthr Outstanding Principal
OutstandingPrincipal
54500
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
366000
CY2022Q3 gthr Convertible Notes Payable Current1
ConvertibleNotesPayableCurrent1
54500
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 gthr Common Stock Shares Issued1
CommonStockSharesIssued1
35333319
CY2021Q4 gthr Common Stock Shares Issued1
CommonStockSharesIssued1
35333319
CY2022Q3 gthr Common Stock Shares Outstanding1
CommonStockSharesOutstanding1
34083319
CY2021Q4 gthr Common Stock Shares Outstanding1
CommonStockSharesOutstanding1
34083319
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
816667
gthr Consulting Fee Expense
ConsultingFeeExpense
24500
gthr Common Stock Issued On Conversion
CommonStockIssuedOnConversion
433333
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
13000
gthr Common Stock Issued Per Share
CommonStockIssuedPerShare
0.03
CY2021Q1 gthr Restricted Share Issued To Consultant
RestrictedShareIssuedToConsultant
1500000
CY2021Q1 gthr Consulting Fee Expense
ConsultingFeeExpense
55500
CY2021Q2 gthr Restricted Share Issued To Consultant
RestrictedShareIssuedToConsultant
3000000
CY2021Q2 gthr Consulting Fee Expense
ConsultingFeeExpense
180000

Files In Submission

Name View Source Status
0001575872-22-001091-index-headers.html Edgar Link pending
0001575872-22-001091-index.html Edgar Link pending
0001575872-22-001091.txt Edgar Link pending
0001575872-22-001091-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gt001_ex31-1.htm Edgar Link pending
gt001_ex31-2.htm Edgar Link pending
gt001_ex32-1.htm Edgar Link pending
gt001_ex32-2.htm Edgar Link pending
gthr-20220930.htm Edgar Link pending
gthr-20220930.xsd Edgar Link pending
img01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
gthr-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
gthr-20220930_pre.xml Edgar Link unprocessable
gthr-20220930_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gthr-20220930_def.xml Edgar Link unprocessable
gthr-20220930_lab.xml Edgar Link unprocessable